Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza Nature
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials Nature
News
Q&A
Shopping
Auction
Rakuten
amazon